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Proto-oncogene expression in peripheral blood mononuclear
cells in IgA nephropathy
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Proto-oncogene expression in peripheral blood mononuclear cells in
IgA nephropathy. We have investigated the expression of proto-onco-
genes in mononuclear cells obtained from patients with IgA nephrop-
athy using a RNA hybridization technique. Patients with IgA nephrop-
athy expressed more c-myc, c-raf, c-fos, and c-jun proto-oncogene
RNA than did normal controls. However, no significant expression of
c-N-ras, c-mos or c-myb genes was found in the mononuclear cells of
these patients. When the amount of urinary protein excretion was used
as an indicator of disease activity (> 1 g/day), a positive correlation was
found between c-myc, c-raf, c-fos, and c-jun expression and urinary
protein excretion (P < 0.01). The expression of these genes correlated
also with the serum IgA concentration (P < 0.01), IgA immune complex(P < 0.01), and histopathological changes in renal tissues obtained from
patients with IgA nephropathy (P < 0.01), The results of this survey
suggest that abnormally regulated proto-oncogene expression in mono-
nuclear cells may play an important role in the progression of IgA
nephropathy and may be useful as an indicator of disease activity and/or
prognosis.
IgA nephropathy (IgAN) is recognized worldwide as one of
the most common primary glomerulonephritides. Since the
original description in 1968, extensive efforts to define the
pathogenesis of this disease have been made [1, 2]. Despite
such efforts the pathogenesis and factors associated with the
severity and progression of the disease remain unclear. The
serum IgA concentration is elevated in as many as 50% of
patients [3]. It has been postulated that altered T-cell function
may explain the increased production of IgA and that altered
T-cell function may play a key role in the pathogenesis of IgAN
[4].
Recently, it has become clear that cellular proto-oncogenes
can regulate cell growth, proliferation, and differentiation [5].
Proto-oncogenes represent the cellular counterparts of trans-
forming DNA sequences isolated initially from acutely trans-
forming retroviruses. Proteins encoded by proto-oncogenes are
candidate for regulators of lymphocyte proliferation. Although
recent studies have shown that some proto-oncogenes are
expressed transiently in peripheral blood mononuclear cells
(MNC) from patients with the autoimmune disease, systemic
lupus erythematosus [6—8] and from normal humans alter stim-
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ulation with mitogens [9, 10], little is known about proto-
oncogene expression in MNC from patients with IgAN.
We, therefore, first used cDNAs for different proto-onco-
genes as hybridization probes to screen for proto-oncogene
expression at the RNA level in MNC from patients with IgAN.
Cellular proto-oncogenes encode proteins with three major sites
of action: the cell-surface membrane, cytosol, and nucleus. The
group of proto-oncogenes which act on the nucleus includes
c-myc, c-fos, c-jun, and c-myb and the group which act on the
cytoplasm includes c-ras, c-mos, and c-raf [11]. It has been
suggested that the products of the former proto-oncogenes may
function in the nucleus as transcriptional regulators and the
products of the later may function in the cytoplasm to regulate
levels of critical second messenger molecules [11]. Our results
indicate that patients with IgAN have increased expression of
c-myc, c-raf, c-fos, and c-jun RNA when compared to normal




Twenty-three patients with IgAN were selected randomly
from patients who are currently being followed at our hospital
(Division of Nephrology, Department of Medicine, Juntendo
University School of Medicine, Tokyo, Japan). The mean age
of the patients was 33.0 (range 16 to 56) years. This group was
comprised of 18 men and 5 women. Ten normal volunteers
served as controls. This control group was comprised of eight
men and two women. Their mean age was 31.6 years. The
diagnosis of IgAN was made by renal biopsy. None of the
patients had clinical or laboratory findings of liver disease,
systemic disease or Henoch SchOnlein purpura. The amount of
proteinuna was used as an indicator of IgAN disease activity.
The patients were judged clinically active when their 24-hour
urinary protein exceeded 1.0 g and clinically inactive when it
was less than 1.0 g. The clinical and laboratory profiles of the
patients are shown in Table 2. Circulating IgA immune complex
(IgA-IC) was measured by solid-phase anti-C3 Facb EIA (Teijin
Lab., Tokyo, Japan) [12]. The histopathological changes seen in
patients with IgAN were classified into four grades as previ-
ously described [13]. Briefly, the minimal stage (grade I) was
characterized by minimal thickening of the mesangium. The
slight state (grade II) was characterized by slight thickening of
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Fig. 1. Hybridization of the c-myc probe to total RNA extracted from
peripheral MNC of patients with IgA and normal individuals. The RNA
extracts from MNC were dotted onto a nylon filter. The amount of
RNAs in each (sg) dot is shown along the left side. The filter was
hybridized with a random primer labeled specific c-myc proto-oncogene
DNA probe. Each number designates a different person. Numbers with
a, b, and c designate the same patient, respectively, before (a) and after
(b), (c) clinical remission with treatment.
mesangial areas, with mild mesangial cell proliferation. The
moderate stage (grade III) was characterized by diffuse mesan-
gial thickening, mesangial cell proliferation, and segmental
thickening of glomerular capillary walls. In addition to changes
observed in the moderate stage, the advanced stage (grade IV)
showed capsular adhesion, fibrocellular crescents, glomerular
hyalinosis, and/or sclerosis.
Mononuclear cell isolation
Heparinized peripheral blood was layered on Ficoll-Hypaque
and centrifuged at 1,500 rpm for 20 minutes. MNC were
collected, counted, and then were stored at —70°C until RNA
preparation.
RNA preparation and cDNA probes
RNA was isolated using vanadylribonucleoside [14]. Total
cellular RNA was applied to nylon filters (New England Nu-
clear, Boston, Massachusetts, USA) in the amounts indicated
(Fig. 1) using a 96-well vacuum manifold. For Northern blots,
RNA samples (5 sg) were denatured and electrophoresed
through 0.7% agarose gels containing 2.2 M formaldehyde and
transferred by capillary blotting onto nylon filters. Hybridiza-
tion was performed in a buffer comprised of 1% crystalline
Fig. 2. Hybridization of the c-raf probe to total RNA extracted from
peripheral MNC of patients with IgAN and normal individuals. The
RNA extracts from MNC were spotted onto a nylon filter. The filter was
hybridized with a random primer labeled specific c-raf proto-oncogene
DNA probe. The amount of RNA in each spot is shown along the left
side. Patients and normal individuals were the same as shown in Fig. 1.
grade bovine serum albumin/i mM EDTA/0.5 M NaHPO4, pH
7.2/7% NaDodSO4 for 20 hours at 65°C with labeled random
primer cDNA probes (Random Primed cDNA labeling kit,
Boehringer-Manheim-Yamanouchi, Tokyo, Japan) as previ-
ously reported [15, 161. Filters were washed two times at 65°C
in 0.5% fraction V-grade bovine serum albumin/i m
Na2EDTA/40 mrvi NaHPO4, pH 7.2/5% NaDodSO4. The filters
were transferred to another such wash, followed by three
washes in 1 mtvi Na2EDTA/40 mrvt NaHPO4, pH 7.2/i%
NaDodSO4 for 10 minutes each. One additional wash in 40 m
NaHPO4, pH 7.2 was done to remove NaDodSO4 [15]. Filters
were air-dried and UV irradiated for five minutes. Filters were
then exposed to Kodak X-OMAT AR film at —70°C with the aid
of intensifying screens and then scanned with a Shimazu
densitometer (Tokyo, Japan).
We used the following fragments as oncogene probes: c-myc
(1.8 kb, 3rd exon, Oncor, Gaithersburg, Maryland, USA),
v-mos (0.9 kb, Ava I-Hind III fragment, Oncor), v-myb (i.8 kb,
Eco RI-Xba I fragment, Oncor), c-N-ras (0.5 kb, Eco RI-Barn
HI fragment, Oncogene Science, Manhasset, New York, USA),
c-raf (1.0 kb, Bgl II-Hpa I fragment, Oncogene Science), c-fos
(8.8 kb, Eco RI fragment), and v-jun (0.95 kb, Eco RI-Barn HI
fragment) which was a gift from the Japanese Cancer Research
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Fig. 3. Hybridization of the c-fos probe to total RNA extracted from
peripheral MNC of patients with IgAN and normal individuals. The
RNA extracts from MNC were dotted onto a nylon filter. The filter was
hybridized with a random primer labeled specific c-fos proto-oncogene
DNA probe. The amount of RNA in each spot is shown along the left
side. Patients and normal individuals were the same as shown in Fig, 1.
Bank (JCRB). A f3-actin cDNA probe was obtained from Dr.
D.W. Cleveland, University of California, San Francisco, Cal-
ifornia.
Statistical analysis
The Spearman rank correlation coefficient was used to assess
the statistical significance of conclusions regarding clinical data,
histological grade, and proto-oncogene expression.
Results
Increased expression of c-myc (Fig. 1), c-raf (Fig. 2), c-fos
(Fig. 3), and c-jun (Fig. 4) was found in MNC from patients with
IgAN, whereas low or undetectable levels of c-N-ras, c-mos
and c-myb were found in this disease (Table 1). No proto-
oncogenes could be detected in MNC from normal individuals
[Figs. 1, 2, 3, 4]. There was no significant difference in the
expression of /3-actin between patients and normal individuals
(Fig. 5).
Under the hybridization conditions used, no abnormally-
sized proto-oncogene transcript was detected by Northern
hybridization (Fig. 5). In our samples, fos-specific mRNA
transcripts were detected and no unspliced precursor 3.5 kb
mRNA [171 was present. Two transcripts of c-jun were ob-
served, a major 2.7 kb and a minor 12 kb species.
The magnitude of increased expression of the four proto-
Fig. 4. Hybridization of the c-jun probe to total RNA extracted from
peripheral MNC of patients with IgAN and normal individuals. The
RNA extracts from MNC were spotted onto a nylon filter, The filter was
hybridized with a random primer labeled specific c-jun proto-oncogene
DNA probe. The amount of RNA in each spot is shown along the left
side. Patients and normal individuals were the same as shown in Fig. 1.
oncogenes varied among the patients (Table 1). As shown in
Tables 1 and 2, patients whose 24-hour urinary protein was
more than 1.0 g had increased expression of these genes (P <
0.01). There was also a positive correlation between the histo-
logical grade, presence of IgA-IC and c-myc, c-raf, c-fos, and
c-jun expression (P < 0.01). The patients whose histological
grade was I or II had lower proto-oncogene expression thari the
patients whose grade was III or IV (P < 0.01). Only patient 23,
whose grade was III, had low proto-oncogene expression.
In these studies, we evaluated the clinical course of seven
patients during hospitalization. Respectively, they received:
prednisolone, dipyridamole and heparin; sulindac and dipyri-
damole; cilostazol, dilazep dihydrochloride, and mefenamic
acid; dipyridamole; methylprednisolone, heparin and cilosta-
zol; warfarin and cilostazol; and prednisolone, heparin and
cilostazol. As shown in Figure 6, patient 10 had heavy protein-
uria on admission. After prednisolone, dipyridamole and hep-
arm were administered, urinary protein decreased gradually. At
discharge, his proteinuna was only one-fifth that at admission.
Creatinine clearance did not change during treatment but mi-
croscopic hematuna and erythrocyte casts had decreased. The
levels of c-myc, c-raf, c-jun and c-fos gene expression were
elevated on admission but the expression of these genes de-
creased gradually as proteinuna was reduced by the treatment
(Fig. 6, Table 1). These genes were expressed at levels eight to
IgA nephropathy IgA nephropathy
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Table 1. Proto-oncogene expression in peripheral blood mononuclear cells of patients with IgA nephropathy and normal individuals
nine fold higher at admission than at discharge. These findings
suggest that abnormal proto-oncogene expression may be asso-
ciated with disease activity.
Patient 12, who was treated with dipyridamole and sulindac,
had a gradual reduction in urinary protein. Creatinine clearance
did not change. In this case, the expression of c-myc and c-jun
gene was elevated at admission and this expression too de-
creased with the reduction in urinary protein. Similarly, in all of
the other patients, c-myc and c-fos expressions were clearly
elevated on admission and then became depressed (Figs. I and
3). The expression of c-raf and c-jun, however, was varied
among the patients (Figs. 2 and 4, Table 1). Patient 16 showed
reduced c-myc, c-raf, and c-fos gene expression on discharge
but the level of c-jun expression persisted during hospitaliza-
tion. In our study, we found no direct effect of medication on
gene expression.
Discussion
Peripheral blood MNC from patients with IgAN were studied
for the expression of proto-oncogenes and the concentration of
proto-oncogene mRNA was compared to that of normal con-
trOls. There is evidence that altered T lymphocyte function may
contribute to the pathogenesis of IgAN [4, 18] and to progres-
sion of the disease [19]. We reported here that the expression of
some prOto-oncogenes is elevated in MNC from patients with
IgAN.
The c-myc proto-oncogene encodes nuclear protein that is
thought to be necessary for cell proliferation [20]. Its expression
occurs transiently in growth-stimulated cells and appears to be
an early event that correlated temporally with change from the
GO to the Gi phase. Actively proliferating normal and tumor
cells show comparable levels of c-myc mRNA [20]. In our
study, the level of c-myc RNA was higher in patients with
active disease (Fig. I, Tables 1 and 2) or with histological
evidence of deterioration. Since the c-myc product is a nuclear
protein, one can envisage that deregulation of the c-myc proto-
oncogene may disrupt normal MNC control. The mechanisms
for enhancing c-myc mRNA expression in the MNC of IgAN
patients remains unknown.
It has also been postulated that the increased expression of
Disease" - — Proto-oncogene activity"
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Fig. 6. Clinical course and proto-oncogene expression in MNC from
patient JO, Relationship between urinary protein, hematuria, proto-
oneogene expression and treatment.
Fig. 5. Northern Blot analysis of mRNA for c-myc, c-raf, c-fos, c-fun,
and 13-actin in RNA extracts of MNC from patients with IgAN and
normal individuals. Total cellular RNA was extracted, electrophoresed
(5 g) through 0.7% agarose gel containing formaldehyde, and trans-
ferred to Gene Screen filters. Patients were as shown in Fig. 1. The
positions of the 28S and 18S RNAs are indicated. Note that the
expression of actin mRNA do not vary among the patients and normal
individuals. Lanes ito 4 are patients with IgA nephropathy and lanes 5
to 8 are controls. Lane 1 is patient 6; lane 2, patient 9; lane 3, patient 19;
lane 4, patient 20; lane 5, control 1; lane 6, control 2; lane 7, control 3;
lane 8, control 4.
the c-myc proto-oncogene may be a normal physiological event
in immune responses [21]. In this study, between the presence
of IgA-IC and the serum concentration of IgA corelated with
proto-oncogene expression. It is possible but unlikely that any
change in c-myc expression is induced by the monocyte/
macrophage activation or differentiation mediated by IgA-IC.
Most recently, the proto-oncogene c-mos was found to be
expressed during differentiation of U937 human monocyte cells
into macrophages. Furthermore, the expression of macrophage
characteristics, such as phagocytosis, was shown to depend on
the amount of c-mos RNA present [221. In the present study, we
could not detect even a very low level of c-mos expression after
a one week exposure to indicate that monocyte/macrophage
activation may not exist in IgAN. Presumably, the cells chiefly
responsible for the observed increase in proto-oncogene mRNA
are T lymphocytes, since T cells constitute 75 to 80% of
peripheral MNC and B-cells constitute s5% [21]. Although we
have not excluded the possibility that non-T cells contribute to
the levels of proto-oncogene expression that we measured, we
interpret in this context that in IgAN, monocyte/macrophage
activation or differentiation does not occur.
We also found no abnormally-sized c-myc gene transcript in
patients with IgAN by Northern blot analysis. Because of the
limitations on blood sampling we could not as yet study the
possibility that DNA methylation status or a nuclear binding
factor may trigger c-myc gene expression, decrease the degra-
dation rate of mRNA, or cause gene amplification.
Stimulation of peripheral blood MNC by a variety of agents
such as platelet-derived growth factor (PDGF), anti-OKT 3,
Concanavarin A, lectin, ionomycin, lipopolysaccharide, Staph-
ylococcus A, anti-s, induces a marked increase in c-myc
mRNA levels through both transcriptional and post-transcrip-
tional regulation [23, 24]. Recently we and others have shown
that interleukin-2 receptor levels rise in IgAN [25, 26]. It is of
interest to learn that how the interleukin-2 receptor gene is
regulated in IgAN. This is currently being studied in our
laboratory.
The c-raf gene is the cellular homologue of the transforming
gene of 3611-MSV (v-rat) [271. Balow et al[28] have shown that
c-raf expression is increased by mitogenic stimulation of MNC
from healthy persons. In our experiments, c-raf gene expres-
sion was increased in tandem with the increase in c-myc gene
expression. Thus, activation of this gene may have some
relevance to disease activity in IgAN.
The c-fos gene is the normal cellular homologue of the
transforming gene of FBJ-osteosarcoma virus [29, 30]. c-fos
was not expressed in resting peripheral MNC. After stimulation
with phytohernagglutinin, however, MNC have elevated c-fos
expression. This returns quickly to baseline with an early but
more protracted induction of c-myc [211. In our study, normal
controls had no detectable c-fos transcription and only patient
20 had prolonged expression of c-fos mRNA (Fig. 3, Table 1).
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Table 2. Clinical and laboratory characteristics of patients with IgA nephropathy
Laboratory evaluationc
Histological C SIgA IgA-IC U-P
Patienta chang&' mi/mm mg/dl jg/m1 giday
H-U
RBCIhpf
II 94.8 293 1.6 0.8 many
2 III 60.9 341 2.4 3.4 many
3 III 59.4 287 1.8 8.4 many
4 III 30.2 342 1.5 5.2 many
5 III 92.3 372 1.9 2.6 1-5
6 III 32.8 380 2.3 2.5 1-5
7 I 96.7 330 1.4 0.5 1-5
8 III 6.4.4 327 1.8 1.4 1-5
9 III 88.4 387 2.2 1.2 1-5
ioa III 88.8 360 1.7 5.2 many
75.2 320 — 2.8 1-5
bc 88.5 280 — 1.0 1-5
11 III 82.1 340 2.2 5.0 many
12a II 119.2 260 — 4.0 1-5
l2' 110.4 228 — 1.0 1-5
13 III 75.6 217 1.1 1.2 10-15
14 II 109.2 368 2.6 1.6 1-5
15 III 147.9 311 3.1 0.8 1-5
16a III 107.5 280 1.0 2.9 many
16b 110.1 295 — 1.0 10-15
17 II 116.0 281 0.6 1.2 15-20
18a III 36.8 564 6.7 3.4 many
49.0 597 — 1.7 15-20
18C 54.8 595 — 1.2 1-5
19 III 10.6 312 2.4 6.6 10-15
20a IV 36.1 258 5.4 8.0 many
20b 43.3 290 — 6.1 many
20 58.4 250 — 3.8 many2l III 77.6 305 5.0 3.5 many
2V' 79.4 — — 2.1 many
22 III 107.6 289 3.8 0.3 many
22" 109.0 — — 0.2 many
22C — — — 0.3 many
23 III 144.4 373 1.1 0.3 many
Abbreviations are Car, creatinine clearance; SIgA, serum IgA concentration; IgA-IC, circulating IgA immune complex; U-P,
excretion; H-U, hematuria.
urinary protein
a Patient numbers correspond to those in Fig. 1
b Histological changes were classified into four grades: I = minimal, II = slight, III = moderate, IV = advanced.
C Obtained at the same time of renal biopsy and/or during treatment
Patient 20 had heavy proteinuria and was nephrotic. c-fos
induction is a common nuclear event in the cascade of re-
sponses that follow many different cell-surface stimulation
events. This would permit the cell to modify its response to
repeated stimulation. The immediate-early gene products may
activate the transcription of further target genes that may
regulate long-term responses [311. This long-term responses
may induce following cell stimulation and alter gene expression
to trigger the glomerular damage seen in IgAN.
The jun gene is a cell-derived sequence that has been identi-
fied as the presumed oncogene of avian sarcoma virus 17 [32].
Several studies have recently shown that c-jun codes for the
fos-associated protein 39 [33] and that c-fos gene expression
and the kinetics of induction of both genes are similar [34]. In
this study, both c-jun and c-fos mRNA levels were co-regu-
lated. Only patient 16 had protracted c-jun expression. The
expression of c-jun and c-fos mRNA is an early response event
during the cellular activation. This rapid and transient response
may reflect the increased c-jun and c-fos mRNA levels seen in
the present study.
Although elevated levels of c-myb mRNA have been reported
in active SLE patients [7, 8] and in PHA-stimulated MNC [9],
we found no evidence of c-myb gene activity in any of our
patients with IgAN. This may reflect the differences in patho-
physiology and lymphocyte activation between IgAN and SLE.
Furthermore, we did not find elevated levels of either the mos
or N-ras gene.
In lymphocytes, the biological functions of proto-oncogene
products are a matter of speculation. Because of the technical
difficulty of introducing genes into lymphocytes, the research in
understanding proto-oncogene function in lymphocytes has
lagged behind work with other cell types. It has been shown
that the similarity between lymphocytes and fibroblasts with
regard to proto-oncogene expression and cell cycle progression
is striking [35, 36]. In this context, it is of interest that heparin
suppresses the induction of c-myc and c-fos mRNA in fibro-
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blasts by selectively inhibiting a protein kinase C-dependent
pathway [37].
In the present study, three of seven patients (10, 20 and 22)
were given hepann, and all these patients had reductions in
c-myc and c-fos expression after treatment.
At present, we can not determine if elevated proto-oncogene
expression in IgAN is the cause or consequence of the disease.
Heparin is a potent anticoagulant and it inhibits the proliferation
of several cell types in vivo. Besides its anticoagulant effect,
heparin's antiproliferative effect may dampen the proliferative
response of MNC to a subset of growth factors found in a
complex extracellular environment.
In summary, we demonstrated that abnormal expressions of
several proto-oncogenes are expressed abnormally in MNC
from patients with IgAN and that the levels of proto-oncogene
mRNA correlate with disease activity. We believe that proto-
oncogene expression may be used to monitor disease activity
and to predict disease progression, and that future studies of
differential gene expression will throw new light on the molec-
ular basis of IgAN.
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